Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Símbolo de cotizaciónDARE
Nombre de la empresaDare Bioscience Inc
Fecha de salida a bolsaApr 10, 2014
Director ejecutivoMs. Sabrina Martucci Johnson
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 10
Dirección3655 Nobel Dr Ste 260
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92122-1050
Teléfono18589267655
Sitio Webhttps://www.darebioscience.com/
Símbolo de cotizaciónDARE
Fecha de salida a bolsaApr 10, 2014
Director ejecutivoMs. Sabrina Martucci Johnson
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos